COGNO LUMOS2 now officially open in Australia
|
|
|
COGNO is excited to announce that the LUMOS2 trial in relapsed grade 2 and/or 3 IDH-mutant glioma has now officially opened in Australia! In further good news, the first participant has been enrolled in September 2023 at the Peter MacCallum Cancer Centre, Melbourne. This participant’s tumour has been successfully profiled and also reviewed by the trial’s Molecular Tumour Advisory Panel, with the participant now assigned to an interventional arm provided within the LUMOS2 trial. A second trial site, St Vincent’s Hospital NSW, has also been activated this week.
In achieving this important milestone, we wish to acknowledge the exceptional leadership of Trial Chair Professor Hui Gan, Medical Oncologist from the ONJCRI. We thank all collaborating partners, in particular Professor David Thomas and the team at Omico, for providing access to their expertise and support in molecular profiling for study participants.
We would like to commend and thank the very significant efforts of the team from the NHMRC Clinical Trials Centre, the trial sponsor University of Sydney, site investigators and trial coordination teams as well as the Australian Trial Management Committee in successfully bringing this trial to Australian patients.
We also wish to acknowledge the Medical Research Future Fund (MRFF) and Australian Brain Cancer Mission (ABCM) for their support of the trial, as well as the industry partners including Akesobio Australia, Antengene, Kazia Therapeutics and Aucentra Therapeutics. In addition, Canadian sites will also be supported by FORUS Therapeutics with funding provided by the Canadian Cancer Society and Brain Canada, with trial oversight by the Canadian Cancer Trials Group (CCTG).
Further information regarding the study can be found in the attached information and via https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=384830&isReview=true
We would strongly encourage referral of any potential participants to relevant sites when activated. Any study queries can be sent to LUMOS2.study@sydney.edu.au.
COGNO looks forward to progressing activation of the LUMOS2 study across all remaining Australian study sites as well as internationally with our colleagues at the Canadian Cancer Trials Group (CCTG).
Associate Professor Eng-Siew Koh
MBBS FRANZCR
Chair, Cooperative Trials Group for Neuro-Oncology (COGNO)
e: cogno@cogno.org.au | w: www.cogno.org.au |
|
|
| Attachment |
|